Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) causes a platelet aggregation defect.
about
Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) causes a platelet aggregation defect.
description
1996 nî lūn-bûn
@nan
1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Combination chemotherapy for b ...... a platelet aggregation defect.
@ast
Combination chemotherapy for b ...... a platelet aggregation defect.
@en
type
label
Combination chemotherapy for b ...... a platelet aggregation defect.
@ast
Combination chemotherapy for b ...... a platelet aggregation defect.
@en
prefLabel
Combination chemotherapy for b ...... a platelet aggregation defect.
@ast
Combination chemotherapy for b ...... a platelet aggregation defect.
@en
P2093
P1476
Combination chemotherapy for b ...... a platelet aggregation defect.
@en
P2093
P304
P356
10.1002/(SICI)1097-0215(19960410)66:2<159::AID-IJC3>3.0.CO;2-1
P577
1996-04-01T00:00:00Z